8-K: PepGen Announces Second Quarter 2024 Financial Results and Clinical Trial Updates

PepGen reported its Q2 2024 financial results, along with positive clinical trial updates for its Duchenne muscular dystrophy and myotonic dystrophy programs.

Summary

• PepGen announced its financial results for the quarter ended June 30, 2024, along with updates on its clinical programs.
• The company reported positive data from the 5 mg/kg dose cohort of the CONNECT1-EDO51 trial for Duchenne muscular dystrophy (DMD), showing a mean exon skipping level of 2.15% and a mean muscle-adjusted dystrophin production increase of 0.70% after three months of dosing.
• The FREEDOM2-DM1 clinical trial for myotonic dystrophy type 1 (DM1) has been cleared by Health Canada and the U.K. Medicines and Healthcare products Regulatory Agency, with initial dosing expected in the second half of 2024.
• PepGen anticipates reporting clinical results from the FREEDOM-DM1 trial in the fourth quarter of 2024.
• The company's cash, cash equivalents, and marketable securities totaled $161.3 million as of June 30, 2024, which is expected to fund operations into 2026.
• Research and development expenses were $25.1 million for the quarter, compared to $16.9 million for the same period in 2023.
• The net loss for the quarter was $28.3 million, or $(0.87) per share, compared to a net loss of $19.5 million, or $(0.82) per share, in the same period of 2023.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data, regulatory progress, and a strong cash position, indicating a positive outlook for the company. However, the increased net loss and R&D expenses temper the overall sentiment slightly.

Positives

• The 5 mg/kg dose of PGN-EDO51 was well tolerated in the CONNECT1-EDO51 trial, with no discontinuations, dose interruptions, or dose reductions.
• All patients in the 5 mg/kg cohort of the CONNECT1-EDO51 trial experienced increases in dystrophin production.
• The FREEDOM2-DM1 trial has received regulatory clearance in Canada and the UK, allowing for patient dosing to begin in the second half of 2024.
• PepGen's strong cash position of $161.3 million is expected to fund operations into 2026.

Negatives

• The company reported a net loss of $28.3 million for the quarter ended June 30, 2024, which is an increase from the $19.5 million loss in the same period of 2023.
• Research and development expenses increased to $25.1 million for the quarter, compared to $16.9 million in the same period of 2023.

Risks

• There are risks associated with the successful initiation and completion of clinical trials, including the CONNECT1, CONNECT2, FREEDOM, and FREEDOM2 trials.
• The interpretation of clinical and preclinical study results may be incorrect, and the company may not observe the anticipated levels of therapeutic activity.
• Product candidates may not be safe and effective or demonstrate safety and efficacy in clinical trials.
• Regulatory interactions may result in delays or adverse outcomes, including delays in regulatory review or clearance to proceed with clinical studies.
• Unexpected increases in expenses or other events could adversely impact the company's financial resources and cash runway.
• The company is dependent on third parties for some aspects of product manufacturing, research, and testing.

Future Outlook

PepGen anticipates reporting initial results from the 10 mg/kg cohort of CONNECT1-EDO51 in early 2025 and clinical results from the FREEDOM-DM1 trial in the fourth quarter of 2024. The company expects to open the CONNECT2 clinical trial in the United States by year-end, subject to regulatory clearance. The company's cash runway is expected to extend into 2026.

Management Comments

• James McArthur, Ph.D., President and CEO of PepGen, stated that the July readout of the CONNECT1 5 mg/kg clinical data was the culmination of years of dedicated effort.
• Mr. McArthur also noted that PGN-EDO51 produced higher mean levels of exon skipped transcript at lower doses and in a shorter period than other exon 51 therapies.
• Management believes that the EDO platform has the potential to dramatically improve the lives of people living with severe neuromuscular and neurological diseases.

Industry Context

PepGen's focus on oligonucleotide therapies for neuromuscular and neurological diseases aligns with a growing trend in the biotechnology industry towards targeted genetic therapies. The positive data from the CONNECT1-EDO51 trial positions PepGen as a potential competitor in the DMD treatment space, while the progress of the FREEDOM-DM1 trial addresses an unmet need in DM1 treatment.

Comparison to Industry Standards

• The reported 2.15% mean exon skipping level in the CONNECT1-EDO51 trial is notable, as it was achieved at a lower dose (5 mg/kg) and in a shorter period (3 months) compared to some other exon 51 therapies in development, such as Sarepta Therapeutics' eteplirsen and casimersen.
• The 0.70% increase in mean muscle-adjusted dystrophin production is also a positive signal, although direct comparisons to other therapies are difficult due to differences in trial design and measurement methods.
• The regulatory clearance for the FREEDOM2-DM1 trial in Canada and the UK is a significant step forward, as it allows PepGen to expand its clinical program for DM1, a disease with limited treatment options. Companies like Biogen and Ionis Pharmaceuticals are also developing therapies for DM1, making this a competitive space.

Stakeholder Impact

• Shareholders may view the positive clinical trial data and strong cash position favorably.
• Employees may be encouraged by the progress of the company's clinical programs.
• Patients with DMD and DM1 may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• PepGen plans to present additional results from the 5 mg/kg cohort of CONNECT1-EDO51 at a medical meeting later in the year.
• The company expects to report initial results from the 10 mg/kg cohort of CONNECT1-EDO51 in early 2025.
• PepGen anticipates reporting clinical results from the FREEDOM-DM1 trial in the fourth quarter of 2024.
• The company expects to initiate patient dosing in the FREEDOM2-DM1 trial in the second half of 2024.
• PepGen continues to advance PGN-EDO53 in investigational new drug (IND) and CTA enabling nonclinical studies.

Key Dates

Keywords

PepGen, Duchenne Muscular Dystrophy, Myotonic Dystrophy, PGN-EDO51, PGN-EDODM1, Clinical Trial, Exon Skipping, Dystrophin, Oligonucleotide Therapy, Neuromuscular Disease